Tranzyme Pharma Announces First Quarter 2013 Financial Results
May 09, 2013 16:30 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 9, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) ("Tranzyme"), a biopharmaceutical company focused on discovering, developing and commercializing novel,...
Tranzyme Pharma to Report First Quarter 2013 Financial Results
May 02, 2013 05:10 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., May 2, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report first quarter 2013 financial results after the close of the...
Tranzyme Pharma and Ocera Therapeutics Announce Merger Agreement
April 23, 2013 19:37 ET
|
Ocera Therapeutics, Inc.
$20M Committed PIPE Financing to Close With Merger
– Joint Conference Call Scheduled for April 24, 2013 at 8:00am ET –
RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, April 23, 2013...
Tranzyme Pharma Announces Fourth Quarter and Full-Year 2012 Financial Results
March 28, 2013 16:30 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., March 28, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel,...
Tranzyme Pharma to Report Fourth Quarter and Full-Year 2012 Financial Results
March 13, 2013 17:55 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., March 13, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that the Company will report fourth quarter and full-year 2012 financial results after...
Tranzyme Pharma Announces Exploration of Strategic Alternatives
February 08, 2013 05:10 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Feb. 8, 2013 (GLOBE NEWSWIRE) -- Tranzyme, Inc. (Nasdaq:TZYM) announced today that its Board of Directors has made a determination to explore and evaluate strategic...
Tranzyme Pharma Promotes David Moore to Chief Business Officer
January 15, 2013 05:10 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 15, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced that David S. Moore has been named as Chief Business Officer.
"Dave has provided...
Tranzyme Pharma Announces Successful Completion of Drug Discovery Collaboration With Bristol-Myers Squibb
January 04, 2013 05:10 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2013 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule...
Tranzyme Pharma's DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results
December 17, 2012 08:00 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b...
Tranzyme Pharma Announces Resignation of Chief Financial Officer
December 05, 2012 16:15 ET
|
Ocera Therapeutics, Inc.
RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Tranzyme Pharma (Nasdaq:TZYM), today announced that Richard I. Eisenstadt, Vice President, Finance and Chief Financial Officer, has...